Navigation Links
Genoptix Announces Pricing of Secondary Public Offering
Date:2/29/2008

CARLSBAD, Calif., Feb. 29 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), today announced the pricing of 2,086,957 shares of outstanding common stock being offered by certain existing stockholders to the public at the price of $25.50 per share. Genoptix, Inc. will not receive any proceeds from the sale. The offer is expected to close on March 5, 2008.

The offering is being made through an underwriting syndicate led by Lehman Brothers, Inc. acting as sole book-running manager. Banc of America Securities LLC and UBS Investment Bank are acting as joint lead managers with Cowen and Company, LLC as co-manager. The selling stockholders have granted the underwriters a 30-day option to purchase up to 313,043 additional shares of common stock.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 28, 2008. This offering is being made by the existing stockholders solely by means of written prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, by contacting Lehman Brothers, Inc., c/o Broadridge Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, NY 11717, fax: 631-254-7140, or e-mail: qiana.smith@broadridge.com, or at the Securities and Exchange Commission's website: http://www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Actual results may differ materially from those projected. Genoptix disclaims, however, any intent or obligations to update these forward-looking statements.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genoptix, Inc. Announces Pricing for Initial Public Offering
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
4. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Cosmetic surgeon Dr. Mark Youssef ... 2014, incorporating the injectable filler into his menu of services to give his patients ... than a year later, he’s still improving his approach to ensure he stays at ...
(Date:5/3/2016)... ... May 03, 2016 , ... Excessive panting in the car or cowering when ... owners often think anxiety only manifests itself as trembling or ‘tail between the legs,’ ... things that be done about it,” says Dr. Jim Lowe, technical services veterinarian for ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... that it is launching a new client service center in La Vergne, Tennessee, ... and will provide the full range of Empyrean client services. , “Our Nashville-area ...
(Date:5/3/2016)... ... May 03, 2016 , ... Each year, about 800,000 people suffer ... across the United States and account for one death every four minutes. Many ... permanently disabled. HCR ManorCare is launching a video series called “Your Brain,” in conjunction ...
(Date:5/3/2016)... ... 03, 2016 , ... United Benefit Advisors (UBA), the nation’s ... latest addition to its elite stable of Partner Firms. Benefits Alliance Insurance Services ... and Paul Vincent. The Firm is also led by industry and thought-leading COO ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 4, 2016 ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved ... are expected to be developed in coming years. Many ... techniques. Cancer stem cell therapies are also expected to ...
(Date:5/3/2016)... Germany , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further ...    Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... May 3, 2016  As a teenager, an active ... fever, which damaged his heart. He continued enjoying sports ... June 2013, Shepherd,s heart was giving out and he ... June 20, 2013, the Mesa, Arizona ... (TAH-t). Like a heart transplant, the SynCardia TAH-t is ...
Breaking Medicine Technology: